STOCK TITAN

Cue Biopharma Q3 2026 loss widens to $50M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Cue Biopharma, Inc. reported third-quarter 2026 results and clinical updates. Revenue was $132,000, down from $2,149,000 in third-quarter 2025, while net loss was $50,016,000 versus $7,448,000. Research and development expense was $17,015,000 and general and administrative expense was $29,826,000; R&D growth reflected clinical-trial start-up costs and non-cash stock-based compensation, while G&A growth primarily reflected non-cash stock-based compensation. Cash and cash equivalents totaled $57,939,000 as of September 30, 2026. In November, an amendment to the ImmunoScape license agreement increased Cue’s right to receive payments to $5,500,000, scheduled in installments through the fourth quarter of 2027.

In CUE-221’s Phase 2 CSU study, 78% of patients with baseline IgE of at least 300 IU/mL who received 4 mg/kg achieved complete hive resolution at week 12, versus 0% with placebo (P<0.005); a post-hoc analysis found complete response rates of 67% versus 0% (p<0.05). The FDA cleared the food-allergy IND, and CUE-401 began first-in-human Phase 1 dosing in its first cohort.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 2 points

How the balance works

Positive

  • None.

Negative

  • Major pointThird-quarter net loss reached $50,016,000, versus $7,448,000 a year earlier.
  • Moderate pointThird-quarter revenue fell to $132,000 from $2,149,000 a year earlier.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Revenue $132,000 Three months ended September 30, 2026; $2,149,000 in the same period of 2025.
Net loss $50,016,000 Three months ended September 30, 2026; $7,448,000 in the same period of 2025.
Research and development expense $17,015,000 Three months ended September 30, 2026; $4,754,000 in the same period of 2025.
General and administrative expense $29,826,000 Three months ended September 30, 2026; $4,939,000 in the same period of 2025.
Cash and cash equivalents $57,939,000 As of September 30, 2026.
Complete hive resolution 78% versus 0% with placebo CUE-221 4 mg/kg; patients with baseline IgE of at least 300 IU/mL; week 12; P<0.005.
Complete response 67% versus 0% with placebo CUE-221 post-hoc analysis; p<0.05.
ImmunoScape license agreement payment right $5,500,000 Increased in November 2026; scheduled for payment in the fourth quarter of 2026 and the third and fourth quarters of 2027.
chronic spontaneous urticaria (CSU) medical
"Phase 2 chronic spontaneous urticaria (CSU) study"
Chronic spontaneous urticaria (CSU) is a disease in which red, itchy hives or swollen welts recur for six weeks or more without a clear trigger, often flaring unpredictably and lasting months to years. For investors, CSU represents a defined and persistent patient population where new drugs, regulatory approvals, trial results, or changes in coverage can meaningfully affect treatment demand and a company’s revenue outlook—like a market reshaped by a reliable, long‑term product.
complete hives resolution (HSS7=0) medical
"primary endpoint of complete hives resolution (HSS7=0)"
free IgE suppression medical
"rapid, profound and dose-responsive free IgE suppression"
dual mechanism of action medical
"precision engineered dual mechanism of action"
non-cash stock-based compensation financial
"non-cash stock-based compensation expense recognized in the quarter"
Non-cash stock-based compensation is pay given to employees or directors in the form of company shares or rights to buy shares instead of cash; it shows up on financial statements as an accounting charge even though no cash leaves the company. It matters to investors because it can lower reported profits and increase the number of shares outstanding—like paying with coupons instead of cash—affecting earnings per share and ownership dilution even though the company keeps its cash.
top-up share obligation financial
"revaluation of the top-up share obligation"
Revenue $132,000 Down from $2,149,000 in the third quarter of 2025.
Research and development expense $17,015,000 Compared with $4,754,000 in the third quarter of 2025.
General and administrative expense $29,826,000 Compared with $4,939,000 in the third quarter of 2025.
Net loss $50,016,000 Compared with $7,448,000 in the third quarter of 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false0001645460Massachusetts0001645460dei:FormerAddressMember2026-11-162026-11-1600016454602026-11-162026-11-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 16, 2026

Cue Biopharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-38327

47-3324577

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

100 Chestnut Street, Suite 300

Somerville, Massachusetts

02143

(Zip Code)

(Address of principal executive offices)

 

(617) 949-2680

(Registrant’s telephone number, including area code)

 

40 Guest Street, Boston, MA 02135

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 


☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange
on which registered

Common Stock, par value $0.001 per share

CUE

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 


Item 2.02.

Results of Operations and Financial Condition.

 

On November 16, 2026, Cue Biopharma, Inc. issued a press release announcing financial results for the quarter ended September 30, 2026 and recent business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, except as expressly set forth by specific reference in such a filing.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits:

 

 

 

Exhibit
No.

Description

 

 

99.1

Press Release dated November 16, 2026

 

 

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cue Biopharma, Inc.

Date: November 16, 2026

By:

/s/ Shao-Lee Lin

Name: Shao-Lee Lin

Title: President and Chief Executive Officer

(Principal Executive Officer)

 

 


img239719762_0.jpg

 

Exhibit 99.1

Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights

•
CUE-221 Phase 2 chronic spontaneous urticaria (CSU) findings highlight differentiated clinical benefit and potential to expand the addressable patient population in CSU and food allergy
•
CUE-401 enters clinical development with initiation of first-in-human dosing, achieving key 2026 milestone
•
Operating results reflect expenditures related to initiation of clinical development program expenses and non-cash charges


BOSTON, November 16, 2026 – Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today reported third quarter 2026 financial results as well as recent business highlights.

 

“We are seeing exciting momentum across our portfolio,” said Pasha Sarraf, M.D., Ph.D., chairman of the board of Cue Biopharma. “We believe CUE-221 has the potential to redefine treatment of IgE-mediated diseases by delivering deeper, more durable disease control and expanding the population of patients who can benefit from anti-IgE therapy. The additional clinical and pharmacological findings shared today from our Phase 2 CSU study reinforce CUE-221’s differentiated profile in CSU and provide a strong foundation to advance our food allergy program. In addition, commencement of dosing in our CUE-401 Phase 1 trial marks a significant milestone for Cue Biopharma as our first autoimmune therapeutic candidate enters the clinic.”

 

“Our goal is to move beyond partial protection toward more complete, sustained protection for patients, including those with high baseline IgE who remain underserved by current therapies. In parallel, we are advancing half-life extension efforts for CUE-221, aimed at further enhancing patient convenience,” said Shao-Lee Lin, M.D., Ph.D., president and chief executive officer of Cue Biopharma.

“CUE-401 is a potentially first-in-class dual-agonist, precision engineered by Cue scientists and designed to unlock the potential of TGF-β biology and restore immune tolerance. We believe this differentiated approach offers broad opportunities to address high unmet needs across autoimmune diseases. We look forward to sharing further progress as we advance our portfolio of therapies aimed at delivering durable, disease-modifying benefits across allergic and autoimmune diseases.”

 

 

Business Highlights

CUE-221: Phase 2 CSU Study Results

 


img239719762_0.jpg

 

We announced positive Phase 2 CSU topline results demonstrating highly statistically significant dose responsive clinical impact on the primary endpoint of complete hives resolution (HSS7=0) and statistically significant improvement on the key secondary endpoint of complete response (UAS7=0).

 

Previously reported durable clinical benefit (HSS7=0) at week 28 (12 weeks after the last dose) in the 4mg/kg dose group persisted in the absence of clinically meaningful drug exposure, was not observed at lower doses, and was significantly greater than XOLAIR® (omalizumab) in a post-hoc analysis, implicating biological effects beyond IgE neutralization alone. These findings are consistent with CUE-221’s dual mechanism of action designed to both neutralize IgE and prevent the synthesis of new IgE.

 

The study enrolled patients across a broad range of baseline IgE (median of 427 ng/mL [178 IU/m], range up to 7860, ng/mL, with approximately one-third having high IgE ≥ 720 ng/mL (300 IU/mL).

 

In the study, CUE-221 demonstrated rapid, profound and dose-responsive free IgE suppression. At 4 mg/kg, all patients in the intensive PK subgroup achieved levels below the limit of quantification within hours of dosing with >90% of the overall population achieving these levels at the first post-dose assessment at week 1, including patients with baseline IgE exceeding the XOLAIR® food allergy dosing table. Median free IgE rose at the end of each 4-week dosing interval (26% of baseline at the end of the first dosing interval), with extent of return progressively diminishing at the end of each subsequent dosing interval.

 

In a prespecified subgroup analysis of patients with high baseline IgE ≥ 300 IU/mL, 78% of patients receiving 4 mg/kg achieved complete hive resolution (HSS7=0) at week 12 versus 0% with placebo (P < 0.005). A subsequent post-hoc analysis also demonstrated a statistically significant higher complete response (UAS7=0) rate of 67% versus 0% with placebo (p < 0.05). Together these data suggest that baseline IgE may predict response in CSU and highlight the clinical potential of CUE-221 in patients with high baseline IgE across disease states, including food allergy.

 

Collectively, the Phase 1 and Phase 2 CSU studies of CUE-221 demonstrated favorable and well-tolerated safety profiles, up to 10 mg/kg. No neutralizing antibodies have been observed. The phase 2 study identified 4 mg/kg as the dose at which differentiated clinical benefit emerged relative to lower doses and XOLAIR®. Bioavailability was approximately 50% subcutaneous (SC) compared with intravenous (IV). Taken together, this enables the evaluation of higher exposures aimed at further optimizing efficacy in CSU and expanding the addressable food allergy population to include the 20-30% of patients currently ineligible for treatment with XOLAIR®.

 

The CUE-221 Investigational New Drug (IND) application for food allergy has been cleared by the Food and Drug Administration (FDA), enabling advancement of the clinical development program.


CUE-401 Advancing a Potentially First-in-Class Precision Engineered Dual-Agonist for Autoimmune Disease

•
Initiated the first-in-human Phase 1 trial, with dosing underway in the first cohort.
•
CUE-401, Cue’s lead autoimmune candidate, is designed to regulate inflammation and drive Treg-mediated tolerance.

 

 

 


img239719762_0.jpg

 

Third Quarter 2026 Financial Results
Third quarter revenue was $0.1 million, compared to $2.1 million in the third quarter of 2025. The decrease in 2026 was due to less revenue recognized under our BI Collaboration and License Agreement during the three months ended September 30, 2026, compared to the same period in 2025, reflecting the planned progression of activities under the agreement.

 

Research and development expenses were $17.0 million for the three months ended September 30, 2026, compared to $4.8 million in the third quarter of 2025. The increase was primarily attributable to an increase in clinical trial costs associated with the start-up and initiation of clinical development, as well as non-cash stock-based compensation expense recognized in the quarter, related to long term, performance-based, company-wide incentive equity grants made following the Company's strategic transformation in the second quarter of 2026.

 

General and administrative expenses were $29.8 million for the three months ended September 30, 2026, compared to $4.9 million for the same period in 2025. The increase was primarily attributable to non-cash stock-based compensation expense allocated to general and administrative expense in the quarter as described above.

 

Other income and expense for the three months ended September 30, 2026, primarily comprised a net non-cash loss related to the revaluation of the top-up share obligation for shares the Company may be required to issue to Ascendant under the license agreement upon the achievement of certain milestones.

 

Net loss for the three months ended September 30, 2026, was $50.0 million, compared to $7.4 million in the third quarter of 2025.

As of September 30, 2026, the Company had $57.9 million in cash and cash equivalents. Additionally, pursuant to a Second Amendment to the License Agreement with ImmunoScape, in November 2026, the Company's right to receive a $5.0 million payment was increased to a total of $5.5 million, payable as follows: $3.0 million in the fourth quarter of 2026, $1.5 million in third quarter of 2027, and $1.0 million in the fourth quarter of 2027.

 

 

 

 

 

 

 

 

 

 

 

 

 


img239719762_0.jpg

 

Cue Biopharma, Inc.

Condensed Consolidated Statement of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except share and per share amounts)

 

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Collaboration revenue

 

$

132

 

 

$

2,149

 

 

$

13,695

 

 

$

5,524

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

29,826

 

 

 

4,939

 

 

 

80,543

 

 

 

12,792

 

Research and development

 

 

17,015

 

 

 

4,754

 

 

 

72,919

 

 

 

21,211

 

Loss on fixed asset disposal

 

 

—

 

 

 

51

 

 

 

—

 

 

 

51

 

Gain on lease termination

 

 

(110

)

 

 

—

 

 

 

(120

)

 

 

—

 

Loss on write-off of lease security deposit

 

 

498

 

 

 

—

 

 

 

498

 

 

 

—

 

Total operating expenses

 

 

47,229

 

 

 

9,744

 

 

 

153,840

 

 

 

34,054

 

Loss from operations

 

 

(47,097

)

 

 

(7,595

)

 

 

(140,145

)

 

 

(28,530

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

483

 

 

 

222

 

 

 

819

 

 

 

649

 

Interest expense

 

 

(2

)

 

 

(75

)

 

 

(11

)

 

 

(306

)

Loss on issuance of liability-classified warrants and related issuance costs

 

 

—

 

 

 

—

 

 

 

(90,011

)

 

 

—

 

Changes in fair value of financial instruments

 

 

(3,400

)

 

 

—

 

 

 

21,087

 

 

 

—

 

Total other income (expense), net

 

 

(2,919

)

 

 

147

 

 

 

(68,116

)

 

 

343

 

Net loss

 

$

(50,016

)

 

$

(7,448

)

 

$

(208,261

)

 

$

(28,187

)

Unrealized gain from available-for-sale securities

 

 

—

 

 

 

1

 

 

 

—

 

 

 

1

 

Comprehensive loss

 

$

(50,016

)

 

$

(7,447

)

 

$

(208,261

)

 

$

(28,186

)

Net loss per common share – basic and diluted

 

$

(4.74

)

 

$

(2.22

)

 

$

(28.70

)

 

$

(9.37

)

Weighted average common shares outstanding – basic and diluted

 

 

10,561,814

 

 

 

3,362,311

 

 

 

7,255,392

 

 

 

3,009,035

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cue Biopharma, Inc.

 


img239719762_0.jpg

 

Condensed Consolidated Balance Sheets

(Unaudited, In thousands)

 

 

 

September 30,
2026

 

 

December 31,
2025

 

Assets

 

 

 

 

 

 

Cash and cash equivalents

 

$

57,939

 

 

$

27,136

 

Other assets

 

 

9,316

 

 

 

15,076

 

Total assets

 

$

67,255

 

 

$

42,212

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

Liabilities

 

$

28,857

 

 

$

15,780

 

Stockholders' equity

 

 

38,398

 

 

 

26,432

 

Total liabilities and stockholders’ equity

 

$

67,255

 

 

$

42,212

 

 

 

About CUE-221

CUE-221 (Ascendant-221, UB-221) is a humanized anti-IgE IgG1 monoclonal antibody designed with a precision engineered dual mechanism of action. CUE-221 binds to IgE at sites that are distinct from the binding sites for XOLAIR® or other similar anti-IgE monoclonal antibodies. In doing so, it maintains the capacity of total IgE to bind the CD23 receptor at the surface of B cells, resulting in reduced IgE synthesis. Therefore, CUE-221 is a functionally distinct novel anti-IgE antibody designed to not only neutralize free IgE with high potency, but also to prevent the synthesis of new IgE with the possibility to achieve b-cell quiescence through crosslinking of CD23 which could ultimately result in sustained disease control beyond drug exposure. The CUE-221 Phase 2 clinical trial in CSU produced positive topline results and clinical evidence providing initial validation of the clinical potential of a precision engineered anti-IgE dual mechanism of action. The study also demonstrated fundamental biological differences compared to XOLAIR®.

 

About CUE-401
CUE-401 is a bispecific fusion protein of 2 human cytokines: IL-2 and TGFβ, each engineered in an attenuated form so as to decrease their affinity for their respective cognate receptor to limit the potential for broader off-target or adverse immunomodulatory effects. The design of CUE-401 stemmed from the Nobel Prize winning discovery of the role of regulatory T cells (Tregs) in autoimmunity, granted in 2025, and the recognition that the cytokines IL-2 and TGF-beta, when acting in concert are essential components in establishing immune tolerance by fostering the development of Tregs.

 

About Cue Biopharma

Cue Biopharma (Nasdaq: CUE) is a clinical stage biopharmaceutical company focused on advancing a portfolio of potentially transformative therapies aimed at delivering durable, potentially disease-modifying benefits across immunological disorders. Its lead asset, CUE-221, is a novel anti-IgE antibody with a dual mechanism of action, currently in Phase 2 development for allergic diseases. In addition, Cue developed the Immuno-STAT® platform which selectively targets disease-specific T cells in vivo without broad immune modulation. Its lead autoimmune candidate, CUE-401, is currently the subject of a Phase 1 clinical trial and is designed to regulate inflammation and drive Treg-mediated tolerance.

 

 


img239719762_0.jpg

 

Cue is led by an experienced management team with deep expertise in identifying, acquiring, and advancing promising drug candidates. For more information, please visit www.cuebiopharma.com and follow us on X and LinkedIn.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, the company’s belief regarding the potential benefits and applications of its drug candidates and programs, including its potential benefits to patients suffering from allergic and autoimmune diseases; the company’s plans to further advance its differentiating Immuno-STAT platform and its lead asset, CUE-221, and its lead autoimmune candidate, CUE-401, including expected timing of clinical trial initiation and data readout; the expected benefits from the company’s license agreement with Ascendant; and expectations regarding the company’s growth, and the company’s business strategies, plans, and prospects. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “aim,” “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely,” “promise,” “potential” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans, and objectives are forward-looking statements. Important factors that could cause the company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company’s ability to maintain and establish collaboration, licensing and other arrangements; the company’s limited operating history, limited cash and a history of losses; the company’s ability to obtain adequate financing to fund its business operations; the company’s ability to achieve profitability; potential setbacks in the company’s research and development efforts for its current and future drug product candidates, including negative or inconclusive results from its preclinical studies or clinical trials or the company’s ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; potential challenges associated with clinical trials conducted in China and the company’s access to, and acceptability of, the data therefrom; its ability to secure required FDA or other governmental approvals for its product candidates and the breadth of any approved indication; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company’s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company’s ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise.

 


img239719762_0.jpg

 

 

Investor and Media Contacts

Agnes Lee

Chief Investor Relations & Communications Officer
alee@cuebio.com

 

Marie Campinell

Senior Director, Corporate Communications

ir@cuebio.com
 

Cue Biopharma, Inc.

 

 


Filing Exhibits & Attachments

2 documents

Keep reading